Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XAV 19

Next Previous
Drug Profile

XAV 19

Alternative Names: Anti-SARS-CoV-2 antibodies - Xenothera; XAV-19

Latest Information Update: 10 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenothera
  • Class Antivirals; Polyclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II COVID-19 pneumonia

Most Recent Events

  • 05 Jan 2023 Preliminary efficacy, adverse events, pharmacokinetics and immunogenicity data from a phase-II/III EUROXAV trial in COVID-2019 infections released by Xenothera
  • 12 Dec 2022 Xenothera terminates phase-II/III EUROXAV trial in COVID-2019 infections in Greece, Bulgaria, Spain, Romania and Turkey (IV, infusion) in December 2022 due to low enrollment (EudraCT2020-005979-12) (NCT04928430)
  • 19 Aug 2021 Xenothera completes the phase II POLYCOR trial in COVID-19 pneumonia in France, Martinique and Reunion (NCT04453384)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top